Three-parameter non-linear dose-finder (3PND)
Due to the small-sample, sequential nature of phase I clinical trials, the Bayesian framework is preferred for accurately estimating the MTD We propose a three-parameter non-linear dose-finder (3PND) as a fully Bayesian model-based design. Given the information set The prior distribution 3PND as a graphical modelFigure Some difficulty in prior elicitation is briefly discussed. As noted in the guidance for the use of Bayesian statistics provided by the Food and Drug Administration [